Pacira Pharmaceuticals recalls
Pacira Pharmaceuticals appears in 4 official U.S. recall notices indexed by RecallRadar, most recently on 2024-07-03.
Company names are normalized from agency data (legal suffixes removed), so related firms may appear under separate pages.
Recall summary
| Recall notices | 4 |
|---|---|
| Published | 2013-03-06 to 2024-07-03 |
| By agency | FDA Drug (4) |
| By classification | Class II (4) |
| By status | ongoing (2), terminated (2) |
| Distribution named in notices | US |
Recalls
- Zilretta (triamcinolone acetonide extended-release injectable suspension), 32 mg per vial, Rx only, Manufactured for: Pacira Pharmaceutical…
FDA Drug · Class II · 2024-07-03 · Pacira Pharmaceuticals
Reason: Failed Dissolution Specifications - did not meet the acceptance criteria for IVR Level 3 testing at 9 months 2-8¿C followed by 6 weeks at 25¿C - Drug Vial Label: Zilretta¿ (triamcinolone acetonide extended-release injectable suspension), 32 mg per vial, Rx only, Manufactured for: Pac…
FDA Drug · Class II · 2024-06-19 · Pacira Pharmaceuticals
Reason: Failed Stability Specifications - at 12 months 2-8 degrees C followed by 6 weeks at 25 degrees C. - EXPAREL, Bupivicaine Liposome Injectable Suspension, 1.3%, 266 mg/20 mL (13 mg/mL), Sterile, 20 mL vial, Rx only, Manufactured by: Pacira P…
FDA Drug · Class II · 2019-12-11 · Pacira Pharmaceuticals
Reason: Sub Potent Drug: Out of Specification (OOS) - EXPAREL (bupivacaine liposome injectable suspension), 1.3%, 266 mg/20 mL (13.3 mg/mL) single use vials, INVESTIGATIONAL USE. For Infiltrati…
FDA Drug · Class II · 2013-03-06 · Pacira Pharmaceuticals
Reason: Subpotent; bupivacaine